Clinical Trial Update: A Single Dose Study To Investigate The Pharmacokinetics and Safety Of Dalbavancin In Hospitalized Children Aged 3 Months to 11 Years. [Phase 1]

View source ↗

Summary

A Phase 1 pharmacokinetics and safety study of dalbavancin in hospitalized children aged 3 months to 11 years has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Infections

Drugs mentioned

• Dalvance (dalbavancin)

Snippet

Sponsor: Durata Therapeutics Inc., an affiliate of Allergan plc | Conditions: Bacterial Infections. | Phase 1 | Status: COMPLETED